Ig gene characteristics for VH3-21+ patients in each country
. | Total . | Germany . | Sweden . | Italy . | United States . | Finland . | Australia . |
|---|---|---|---|---|---|---|---|
| No. of VH3-21 cases | 90 | 37 | 32 | 9 | 7 | 3 | 2 |
| Frequency, %* | 6 | 5 | 10 | 5 | 3 | 9 | 3 |
| Mutated/unmutated | 57/33 | 23/14 | 22/10 | 5/4 | 4/3 | 2/1 | 1/1 |
| VH gene homology | |||||||
| At least 98% | 32 | 14 | 10 | 4 | 3 | 1 | 0 |
| 96% to 98% | 41 | 17 | 14 | 4 | 4 | 1 | 1 |
| Less than 96% | 17 | 6 | 8 | 1 | 0 | 1 | 1 |
| κ/λ expression | 10/58 | 1/14 | 5/27 | 1/8 | 3/4 | 0/3 | 0/2 |
| Highly homologous HCDR3 | 36 | 10 | 16 | 5 | 3 | 1 | 1 |
| Moderately homologous HCDR3 | 14 | 6 | 5 | 1 | 1 | 1 | 0 |
| Vλ2-14 functional | 65 | 26 | 24 | 6 | 4 | 3 | 2 |
| Homologous HCDR3 and Vλ2-14 | 46 | 15 | 19 | 5 | 4 | 2 | 1 |
. | Total . | Germany . | Sweden . | Italy . | United States . | Finland . | Australia . |
|---|---|---|---|---|---|---|---|
| No. of VH3-21 cases | 90 | 37 | 32 | 9 | 7 | 3 | 2 |
| Frequency, %* | 6 | 5 | 10 | 5 | 3 | 9 | 3 |
| Mutated/unmutated | 57/33 | 23/14 | 22/10 | 5/4 | 4/3 | 2/1 | 1/1 |
| VH gene homology | |||||||
| At least 98% | 32 | 14 | 10 | 4 | 3 | 1 | 0 |
| 96% to 98% | 41 | 17 | 14 | 4 | 4 | 1 | 1 |
| Less than 96% | 17 | 6 | 8 | 1 | 0 | 1 | 1 |
| κ/λ expression | 10/58 | 1/14 | 5/27 | 1/8 | 3/4 | 0/3 | 0/2 |
| Highly homologous HCDR3 | 36 | 10 | 16 | 5 | 3 | 1 | 1 |
| Moderately homologous HCDR3 | 14 | 6 | 5 | 1 | 1 | 1 | 0 |
| Vλ2-14 functional | 65 | 26 | 24 | 6 | 4 | 3 | 2 |
| Homologous HCDR3 and Vλ2-14 | 46 | 15 | 19 | 5 | 4 | 2 | 1 |
Percent VH3-21 using cases; that is, the number of VH3-21+ cases out of the total number of CLL cases investigated by VH gene sequencing in each cohort